A&O Shearman publishes Life Sciences and Healthcare report
A&O Shearman has published a 36-page report, Life Sciences and Healthcare Insights, with contributions from 20 attorneys. The report is vital reading for Israeli life sciences companies at this precise moment. Israel hosts hundreds of life sciences companies, all attracting serious global capital.
Lee Noyek, head of the firm’s Israel Desk, echoes this sentiment, saying the report examines why life sciences and healthcare companies are attracting heightened attention from activist funds and what boards can do in response.
It also shows how with AI-driven partnerships, acquisitions, and collaborations gathering pace, quality, consent, ownership, and regulatory compliance are increasingly central to deal value and risk allocation. Furthermore, he explains, it analyzes global developments from the deal structures Chinese innovators are using to expand internationally, as well as how the UPC is impacting European patent litigation two years after its launch.
For Israeli firms — combining decades-old digital health infrastructure with world-class computational biology talent and increasingly seeking international partnerships — each of these themes lands with particular force: activist scrutiny as funding rounds grow larger, AI data governance as deal-making accelerates, and China and European patent dynamics as global expansion becomes the next frontier.
Read the report here.
